Phase 3 Win for TED Therapy - Takeaways - MDSpire
Clinical Guidelines
Feature

Phase 3 Win for TED Therapy

Amgen’s subcutaneous TEPEZZA meets phase 3 endpoints in thyroid eye disease

  • May 8, 2026

  • 3 min

Share

  • 1

    Phase 3 trial for subcutaneous TEPEZZA shows 77% proptosis response.

  • 2

    Compared to 19.6% in placebo.

  • 3

    Administered via on-body injector every two weeks.

  • 4

    Improved quality of life and clinical metrics observed.

  • 5

    Most common side effects include muscle spasms and weight loss.

  • 6

    TEPEZZA is the only approved treatment for TED.

  • 7

    Full results to be presented at a medical congress.

Original Source(s)

Phase 3 Win for TED Therapy

  • May 8, 2026

Related Content

Retinal Ischemia as Stroke Warning

Retrospective study investigates links between acute ischemic ocular events and increased stroke risk

  • May 8, 2026

  • 3 min
Vamikibart Shows Early Safety in Uveitic Macular Edema

Phase 1 nonrandomized trial reported no drug-related serious adverse events, but efficacy remains unproven

Chatbots Enter Retinal Care

New research shows how conversational AI might improve patient understanding and engagement in retinal detachment pathways

  • May 7, 2026

  • 3 min